Elevated serum palmitoleic acid levels may predict prognosis of crohn's disease, study finds

Japan: Palmitoleic acid is an adipose tissue-derived mono-unsaturated free fatty acid.

In a study conducted by Yuko Akazawa and the team, it was found that palmitoleic acid (PO) can be used as the indicator of the local inflammation and prognosis in Crohn's disease (CD) patients. 

Inflammatory bowel disorders (IBDs), which include ulcerative colitis (UC) and CD, are chronic intestinal illnesses with unclear etiologies and varying disease extents and outcomes. The use of biomarkers in the diagnosis and treatment of IBDs is thought to be helpful. The aim of this study was to look into the relevance of PO levels in the serum of UC and CD patients. The findings of this study were published in the journal Scientifc Reports on 10th August 2021.

This retrospective investigation was carried out in compliance with the Helsinki Declaration's ethical criteria. From April 2010 to March 2011, the serum study group included 57 IBD patients (35 with CD and 22 with UC). As controls, twenty-two healthy volunteers were recruited. Prior clinical evaluation, endoscopy, and histology were used to confirm the diagnosis of UC or CD using defined criteria. Serum samples were obtained from all IBD patients and healthy participants and stored at 80 °C until use in ethylenediaminetetraacetic acid tubes. MAT was extracted during the colectomy.